Gastric cancer

36 trials 14 recruiting MedDRA PT
36 Registered trials
14 Recruiting
27 Unique sponsors
33 Unique IMPs
32 Commercial trials
Drug classes (ATC)
— ATC code not specified 25
L Oncology (ATC L) 9
V Various (ATC V) 1
H Endocrinology (ATC H) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 17 substances
Monoclonal antibody (immune) 3 substances
Checkpoint inhibitor (PD-1) 2 substances
Kinase inhibitor 2 substances
Monoclonal antibody 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Monoclonal antibody (chimeric) 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
Antibody-drug conjugate (ADC) 1 substance
Antimetabolite 1 substance
Platinum compound 1 substance
Phase III: 7 Phase II/III: 1 Phase II: 5 Phase I/II: 4 Phase I: 15 Phase I (Other): 2 Phase I (First in Human): 2

Filter these 36 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 36 trials

Phase III

7 trials
  • Amgen Inc. Commercial
    BEMARITUZUMAB
    2023-505457-40-00 18 countries 2022 n=327
    Ended
  • Amgen Inc. Commercial
    BEMARITUZUMAB
    2023-505458-16-00 12 countries 2022 n=186
    Ended
  • Astellas Pharma Global Development Inc. Commercial
    PEMBROLIZUMAB; ZOLBETUXIMAB
    2024-519773-19-00 11 countries 2025 n=201 Orphan
    Ended
  • AstraZeneca AB Commercial
    DURVALUMAB
    2023-507338-26-00 8 countries 2021 n=341
    Ended
  • BeOne Medicines AG Commercial
    TISLELIZUMAB
    2025-522862-58-00 6 countries 2026 n=63
    Recruiting
  • Shanghai Henlius Biotech Inc. Commercial
    HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
    2024-516633-12-00 7 countries 2025 n=106
    Recruiting
  • Centre Leon Berard Academic
    BALSTILIMAB; BOTENSILIMAB; FLUOROURACIL; NIVOLUMAB; OXALIPLATIN
    2023-506291-28-00 1 country 2026 n=132
    Recruiting

Phase II/III

1 trial
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    NIVOLUMAB; PUMITAMIG
    2025-523263-37-00 6 countries 2026 n=184
    Recruiting

Phase II

5 trials
  • Bayer Consumer Care AG Commercial
    3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE; BAY 2927088; SEVABERTINIB
    2024-517419-62-00 4 countries 2025 n=37
    Recruiting
  • Blue Earth Diagnostics Ireland Limited Commercial
    GA68-ONCOFAP
    2025-521983-36-00 2 countries n=65
    Pending
  • Jazz Pharmaceuticals Ireland Limited Commercial
    ZANIDATAMAB
    2024-516551-41-00 1 country 2026 n=125
    Recruiting
  • Aalborg University Hospital Academic
    (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE; FLUDEOXYGLUCOSE (18F)
    2023-505916-40-01 1 country 2024 n=20
    Ended
  • Karolinska University Hospital Academic
    OCTREOTIDE
    2022-502745-98-00 1 country 2020 n=172
    Ended

Phase I/II

4 trials
  • Bristol Myers Squibb International Corporation Commercial
    NIVOLUMAB; NIVOLUMAB, RELATLIMAB; RELATLIMAB
    2023-508067-70-00 9 countries 2015 n=1,003
    Ended
  • Bristol Myers Squibb International Corporation Commercial
    IPILIMUMAB; NIVOLUMAB
    2024-516540-25-00 1 country 2013 n=83
    Ended
  • Institut De Recherches Internationales Servier IRIS Commercial
    PEMBROLIZUMAB; SYM025
    2023-507995-33-00 7 countries 2024 n=31
    Ended
  • Seagen Inc. Commercial
    DISITAMAB VEDOTIN; TUCATINIB
    2023-507555-29-00 4 countries 2024 n=68
    Recruiting

Phase I

15 trials
  • Amgen Inc. Commercial
    IMP not specified
    2022-502867-39-00 3 countries 2023 n=58
    Ended
  • BeOne Medicines AG Commercial
    IMP not specified
    2023-506888-34-00 1 country 2024 n=91
    Recruiting
  • BeOne Medicines AG Commercial
    IMP not specified
    2025-523165-19-00 1 country 2026 n=15
    Recruiting
  • BeOne Medicines AG Commercial
    IMP not specified
    2025-524136-19-00 2 countries 2026 n=56
    Recruiting
  • BioNTech Cell & Gene Therapies GmbH Commercial
    CLDN6 CAR-T; CLDN6 CAR-T(A); CLDN6 RNA-LPX; RBP030.2
    2024-514962-38-00 3 countries 2020 n=206
    Recruiting
  • Cullinan Therapeutics Inc. Commercial
    IMP not specified
    2024-511744-27-00 2 countries 2022 n=240
    Ended
  • Fusion Pharmaceuticals Inc. Commercial
    IMP not specified
    2025-521235-37-00 1 country n=45
    Ended
  • Genentech Inc. Commercial
    IMP not specified
    2023-504491-15-00 6 countries 2020 n=187
    Ended
  • Merck Healthcare KGaA Commercial
    IMP not specified
    2025-523232-39-00 1 country n=14
    Pending
  • Nykode Therapeutics ASA Commercial
    IMP not specified
    2023-509996-18-00 2 countries 2022 n=40
    Ended
  • One-carbon Therapeutics AB Commercial
    IMP not specified
    2024-519639-40-00 2 countries 2025 n=33
    Recruiting
  • Seagen Inc. Commercial
    SGN-ALPV
    2022-500094-14-00 3 countries 2022 n=82
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-505858-18-00 4 countries 2024 n=175
    Halted
  • Seagen Inc. Commercial
    IMP not specified
    2023-508469-34-00 2 countries 2020 n=238
    Recruiting
  • Incyte Corp. Academic
    IMP not specified
    2023-504400-29-00 1 country 2022 n=9
    Ended

Phase I (Other)

2 trials
  • Exelixis Inc. Commercial
    IMP not specified
    2024-516477-73-00 2 countries 2018 n=320
    Ended
  • Toray Industries Inc. Commercial
    IMP not specified
    2024-513915-28-00 1 country 2019 n=32
    Ended

Phase I (First in Human)

2 trials
  • Crescent Biopharma Inc. Commercial
    CR-001
    2025-523590-42-00 1 country n=44
    Pending
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
BeOne Medicines AG Commercial 4 Phase I, Phase III 4
Seagen Inc. Commercial 4 Phase I, Phase I/II 2
Amgen Inc. Commercial 3 Phase I, Phase III 0
Bristol Myers Squibb International Corporation Commercial 2 Phase I/II 0
BioNTech Cell & Gene Therapies GmbH Commercial 1 Phase I 1
Cullinan Therapeutics Inc. Commercial 1 Phase I 0
Fusion Pharmaceuticals Inc. Commercial 1 Phase I 0
Genentech Inc. Commercial 1 Phase I 0
Merck Healthcare KGaA Commercial 1 Phase I 0
Nykode Therapeutics ASA Commercial 1 Phase I 0
One-carbon Therapeutics AB Commercial 1 Phase I 1
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase II/III 1
Exelixis Inc. Commercial 1 Phase I (Other) 0
Toray Industries Inc. Commercial 1 Phase I (Other) 0
Bayer Consumer Care AG Commercial 1 Phase II 1
Blue Earth Diagnostics Ireland Limited Commercial 1 Phase II 0
Jazz Pharmaceuticals Ireland Limited Commercial 1 Phase II 1
Astellas Pharma Global Development Inc. Commercial 1 Phase III 0
AstraZeneca AB Commercial 1 Phase III 0
Shanghai Henlius Biotech Inc. Commercial 1 Phase III 1
New trials by year
2019
1
2020
4
2021
1
2022
6
2023
1
2024
5
2025
5
2026
6
← All indication landscapes